Obesity Drug Linked to Suicidal Thoughts
The manufacturer of the antiobesity drug rimonobant, sold under the Acomplia brand, has informed the FDA that users of the medication suffer from a higher risk of suicidal thoughts. Sanofi-Aventis also told the FDA that it doesn't recommend the drug for people who suffer from depression.
Sanofi-Aventis has told the U.S. Food and Drug Administration its rimonobant antiobesity drug, also sold under the Acomplia brand, brings a higher risk of suicidal thoughts than placebo, and it does not recommend the treatment for patients suffering from major depression.